A Southern California native, Dr. Merrill Shum returned to practice medicine in his home community after serving as an attending physician and member of the Crozer Regional Cancer Center, a Fox Chase Cancer Center affiliate in Philadelphia, Pennsylvania, for two years. During his tenure, he served as a relevance reviewer for the Hematology and Medical Oncology section from the American Board of Internal Medicine. He was appointed Clinical Assistant Professor at Temple University’s School of Medicine. Dr. Shum is double-board-certified by the American Board of Hematology and the American Board of Medical Oncology. He completed his fellowship at MD Anderson Cancer Center at Cooper. Dr. Shum earned his medical degree from Autonoma University of Guadalajara in Jalisco, Mexico, and his fifth Pathway Certification from New York Medical College. He completed his residency at UMDNJ- Robert Wood Johnson Medical School (Cooper University Hospital) and served as Chief Institutional Fellow. Prior to this, he graduated from the University of California at Berkeley.
During his residency and fellowship, Dr. Shum received numerous honors and awards including the Arthur P. Gold Foundation Excellence in Humanism and Teaching Award, the Golden Apple Teaching Award, Teaching Resident of the Year Award, Internal Medicine Resident of the Year Award, Cambridge Who’s Who in Medicine, AMA Physician’s Recognition Award, NJ ACP Certificate of Merit, and the IRB Award for Contribution to Education and Research. He presented nationally at NJ ACP, SGIM, Lynn Sage Breast Symposium, San Antonio Breast Cancer Symposium, and internationally at Novo Nordisk Symposium on Hemostasis Management in Copenhagen, Denmark.
As a senior partner and senior medical director for The Oncology Institute, he has helped the center grow into the largest value-based care community oncology practice in the nation. He is the Co-Chair of the Physician Executive Committee and member on the Board of Directors. He has been a lead principal investigator and sub-investigator in over 300 clinical trials and has helped facilitate several FDA drug approvals. He serves on several pharmaceutical drug advisory boards and serves as Pharmacy Director for The Oncology Institute.
Some of Dr. Shum’s most recent accolades and recognitions include Top Doctor 2021 (California Magazine), 2021 Super Doctors Award for Hematology-Oncology (Los Angeles Magazine), as well as the Physicians Achievement Award from the Presbyterian Intercommunity Hospital (PIH). He received the Southern California Rising Star Award (Los Angeles Magazine) for Hematology and Oncology from 2013 to 2015 and Super Doctors Award (Los Angeles Magazine) four years in a row from 2017 through 2021. He was recognized by Vitals’ website for Patient’s Choice Award in 2018 and made Healthgrades’ website Honor Roll.
He has 23 publications that can be found in the American Journal of Medicine, American Journal of Hematology, American Journal of Clinical Oncology, Breast Cancer Research and Treatment, Annals of Oncology, Blood, Proceedings American Journal of Clinical Oncology, Cancer Research, and the Journal of Thoracic Oncology. He has also submitted another abstract to the American Society of Hematology, December 2021.
Dr. Shum is fluent in Spanish and Cantonese Chinese.
American College of Physicians (ACP)
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
Dr. Shum continues to strive to bridge the gap of patient understanding through communication and education. His strong interest in clinical trials allows him to integrate current standard therapies with the latest advances. “While we maintain our integrity through honesty, we must remain compassionate. Our dedication and commitment to achieve the highest quality of care is aimed at improving quality of life and ultimately improving survival. It is our responsibility to help our patients and their families navigate through their cancer management to minimize anxiety through this difficult period.”
8135 S. Painter Ave.
Whittier, CA 90602